Quotient Therapeutics pioneers somatic genomics, unlocking the vast genetic diversity within every human body. By analyzing trillions of somatic genomes, the company identifies genes causally implicated in disease and protective mutations that reveal novel therapeutic pathways. This approach requires only 10 to 30 patients per study, providing genetically validated drug targets across autoimmune, cardiometabolic, rare, and oncology diseases. The company operates through an AI driven platform integrating DNA sequencing, computational biology, and automation. Founded in 2022 by Flagship Pioneering with academic leaders, Quotient combines world class scientific expertise with high throughput R&D to develop breakthrough medicines.
72
Team Members
2022
Founded
Biotechnology
Sector
Hybrid
Work Environment
A world where natural genetic diversity within every person reveals the causes and cures for any disease.
At Quotient, our mission is to transform somatic genomics insights into breakthrough medicines by uncovering genetically validated drug targets from natural mutations.